Harrow (HROW) Competitors

Cytokinetics (NASDAQ:CYTK) and Harrow (NASDAQ:HROW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.

Which has higher valuation & earnings, CYTK or HROW?

Harrow has higher revenue and earnings than Cytokinetics. Harrow is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$19.22M	194.57	-$526.24M	-$5.29	-5.92
Harrow	$212.86M	4.61	-$24.41M	-$0.56	-47.73

Does the MarketBeat Community prefer CYTK or HROW?

Cytokinetics received 735 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 79.94% of users gave Cytokinetics an outperform vote while only 59.87% of users gave Harrow an outperform vote.

Company	Underperform	Outperform
Cytokinetics	Outperform Votes 829 79.94%	Underperform Votes 208 20.06%
Harrow	Outperform Votes 94 59.87%	Underperform Votes 63 40.13%

Is CYTK or HROW more profitable?

Harrow has a net margin of -19.75% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-17,906.25%	N/A	-50.21%
Harrow	-19.75%	-45.57%	-8.87%

Does the media favor CYTK or HROW?

In the previous week, Cytokinetics had 17 more articles in the media than Harrow. MarketBeat recorded 24 mentions for Cytokinetics and 7 mentions for Harrow. Harrow's average media sentiment score of 0.91 beat Cytokinetics' score of 0.83 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	11 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate CYTK or HROW?

Cytokinetics presently has a consensus price target of $74.44, suggesting a potential upside of 137.74%. Harrow has a consensus price target of $61.25, suggesting a potential upside of 129.14%. Given Cytokinetics' higher possible upside, research analysts plainly believe Cytokinetics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Harrow	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, CYTK or HROW?

Cytokinetics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Do insiders & institutionals believe in CYTK or HROW?

72.8% of Harrow shares are held by institutional investors. 2.7% of Cytokinetics shares are held by insiders. Comparatively, 15.2% of Harrow shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cytokinetics beats Harrow on 10 of the 19 factors compared between the two stocks.